Nyrada (ASX:NYR)
ASX announcement history & article coverage
Transparent by design.
Announcments by Nyrada (ASX:NYR) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Change in substantial holding - M Azzi
Cleansing Statement
Application for quotation of securities - NYR
Xolatryp Demonstrates Cardioprotection in Preclinical Study
Nyrada's Xolatryp Shows Sustained Cardioprotection and Anti-Tumour Potential in Preclinical Doxorubicin Study
Nyrada Full Year Results FY2026
Nyrada advances Xolatryp clinical trials, expands oncology pipeline, strengthens IP, and reports solid FY2026 financials
Annual Report for year ended 30 June 2026
Nyrada advances Xolatryp clinical trials, expands pipeline, secures US patent, and strengthens financial position in FY2026
Preliminary Final Report
Nyrada Inc. reports increased loss and lower revenue for FY2026 with no dividends declared
Appendix 4G and Corporate Governance Statement
Change in substantial holding - M Azzi
CSANZ26 Conference Poster
Quarterly Activities Report and Appendix 4C
Nyrada advances Xolatryp Phase IIa trial, secures US patent allowance, and reports strong cash position
Response to ASX Price Query
Nyrada denies undisclosed information amid unusual trading, confirms ASX compliance
Change in substantial holding - M Azzi
PROTECT-MI Phase IIa Clinical Trial Update No 2
Notification of cessation of securities - NYR
Cleansing Statement
Application for quotation of securities - NYR
Cleansing Statement
Application for quotation of securities - NYR
Cleansing Statement
Application for quotation of securities - NYR
Change of Director's Interest Notice - JB
PROTECT-MI Phase IIa Clinical Trial Update